Nurix Therapeutics, Inc. Overview
Pro stress-test →Nurix Therapeutics is advancing a multi-modal pipeline using targeted protein degradation to harness the cell's natural protein degradation machinery for treating cancers and autoimmune diseases. The company maintains strategic collaborations with Gilead Sciences, Sanofi, and Pfizer for co-development and co-commercialization of multiple drug candidates.
Strategic Profile
Pro stress-test →Nurix utilizes an integrated discovery platform incorporating artificial intelligence and ligase expertise to support research activities. The company develops Degrader Antibody Conjugates (DACs) that combine the cell specificity of antibodies with the potency and selectivity of degraders. Recent significant funding of $250 million and recognition as a high-potential small cap stock indicate strong financial backing and market confidence.
Competitive Landscape
Pro stress-test →Omeros, AC Immune, Cullgen, Fate Therapeutics, and Alzinova represent some of 33 competitors in the targeted protein degradation and biopharmaceutical space. Nurix's differentiation centers on its proprietary DELigase platform, established pharma partnerships, and clinical validation of multiple degrader modalities across oncology and immunology indications.
Industry Context
Nurix Therapeutics, Inc. operates in Biopharmaceutical/Targeted Protein Degradation Therapeutics.
Key facts
Founded: 2009 · Headquarters: San Francisco, CA · Employees: 201-500 · Revenue: $84M · Market cap: $1.7B